Sage gains after striking license agreement with Biogen Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Sage Therapeutics (SAGE) up 7% after announcing a global collaboration and license agreement with Biogen (BIIB) to jointly develop and commercialize zuranolone for major depressive disorder, postpartum depression and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders
- Rhythm Pharmaceuticals (RYTM) up 13% after announcing the FDA has approved Imcivree for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin, proprotein convertase subtilisin/kexin type 1 or leptin receptor deficiency confirmed by genetic testing
- Sorrento Therapeutics (SRNE) up 17% after the company announced subsidiary SmartPharm Therapeutics has been awarded a contract from the Defense Advanced Research Projects Agency co-funded by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to develop a rapid countermeasure to COVID-19
LOWER -
- Riot Blockchain (RIOT) down 13% as bitcoin continues to come off recent highs
Symbols:
SAGE BIIB RYTM SRNE RIOT Keywords: Wall Street, Top Stories, Stocks, Pre-market